New pill aims to keep ulcerative colitis in check for a year
NCT ID NCT07459686
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the safety and effectiveness of Velsipity tablets taken daily for up to 52 weeks by people with moderate to severe ulcerative colitis. About 553 participants will be followed in real-world medical settings. The goal is to see if the drug can help control symptoms and reduce serious infections over the long term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tree mushroom drink calm inflammatory bowel disease?
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Can a new pill tame ulcerative colitis Flare-Ups?
- Could a new pill tame ulcerative colitis? a First-in-Human trial aims to find out
- Can a new pill tame ulcerative colitis when others fail?
- Can a pill tame ulcerative colitis? new trial seeks answers